Form 4: Ardelyx CCO Eric Foster Executes Sell-to-Cover Transaction

Chief Commercial Officer Eric Foster sold 7,998 shares of Ardelyx common stock to satisfy tax withholding obligations related to RSU vesting.

Summary

• Eric D. Foster, Chief Commercial Officer of Ardelyx, Inc., sold a total of 7,998 shares of common stock on May 21, 2026.
• The shares were sold at a price of $6.2675 per share.
• The transaction was executed in three separate blocks of 3,166, 2,427, and 2,405 shares.
• Following these transactions, Foster retains beneficial ownership of 417,972 shares of Ardelyx common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and required by the terms of the executive's compensation plan.

Positives

• The sale was non-discretionary and mandated by the terms of the original RSU grant to cover tax liabilities, indicating it was not a signal of lack of confidence in the company.

Negatives

• The transaction results in a reduction of the executive's direct equity stake in the company.

Risks

• None identified; this is a routine administrative transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions are standard practice in the biotechnology sector, where equity-based compensation is a primary component of executive remuneration packages.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for handling tax obligations upon the vesting of restricted stock units.

Stakeholder Impact

• Minimal impact on shareholders as the sale was a mandatory tax-related transaction rather than a discretionary divestment.

Key Dates

Keywords

Ardelyx, ARDX, Form 4, Insider Trading, Equity Compensation, Biotech